Table 3.
Hazard Ratios of Various Timing of Rifampin Treatment and Postrifampin Treatment for Recurrence Across Subgroup Analyses
| Groups | Active Rifampin Treatment | Postrifampin Treatment | |||
|---|---|---|---|---|---|
| Active Rifampin Treatment: Days 1–90 (n = 842) | Active Rifampin Treatment: Days 91–180 (n = 231) | Active Rifampin Treatment: Days 181–731 (n = 88) | Post–Rifampin Treatment: Total ≤90 d (n = 546) | Post Rifampin Treatment: Total >90 d (n = 226) | |
| Total cohort (N = 4624) | 0.60 (.45–.79) | 0.16 (.04–.66) | 0.57 (.18–1.81) | 1.12 (.95–1.31) | 1.07 (.75–1.51) |
| Knee (n = 3779) | 0.55 (.40–.76) | 0.19 (.05–.75) | 0.61 (.19–1.92) | 1.12 (.94–1.33) | 1.17 (.82–1.67) |
| Hip (n = 813) | 0.74 (.40–1.38) | (0–∞)a | (0–∞)a | 1.16 (.79–1.72) | 0.42 (.10–1.72) |
| MSSA (n = 3405) | 0.62 (.43–.89) | 0.26 (.07–1.04) | 0.55 (.13–2.22) | 1.18 (.97–1.45) | 1.01 (.67–1.53) |
| MRSA (n = 1219) | 0.58 (.37–.90) | (0–∞)a | 0.65 (.09–4.99) | 1.01 (.78–1.30) | 1.21 (.65–2.26) |
| Early PJI (n = 1150) | 0.47 (.30–.74) | (0–∞)a | 1.14 (.28–4.70) | 1.07 (.81–1.40) | 0.68 (.38–1.21) |
| Late PJI (n = 1056) | 0.33 (.16–.67) | 0.23 (.03–1.66) | (0–∞)a | 0.94 (.69–1.29) | 1.45 (.83–2.53) |
Data are presented as hazard ratio (95% confidence interval).
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PJI, prosthetic joint infection.
a
Hazard ratio and confidence interval could not be reliably estimated in subgroups having few patients during a given time period and no recurrences.